S&P 500   3,972.35 (-2.85%)
DOW   31,867.80 (-2.41%)
QQQ   296.14 (-3.28%)
AAPL   143.54 (-3.82%)
MSFT   257.25 (-3.59%)
FB   196.07 (-3.23%)
GOOGL   2,263.13 (-2.85%)
AMZN   2,183.86 (-5.35%)
TSLA   731.31 (-3.98%)
NVDA   173.93 (-4.31%)
BABA   89.37 (-2.85%)
NIO   16.25 (-2.29%)
AMD   98.77 (-3.61%)
CGC   5.77 (-2.04%)
MU   72.02 (-3.30%)
T   20.46 (-0.53%)
GE   75.65 (-0.98%)
F   13.02 (-3.77%)
DIS   105.81 (-2.60%)
AMC   13.47 (+4.42%)
PFE   50.58 (-1.48%)
PYPL   78.10 (-2.07%)
NFLX   182.77 (-4.09%)
S&P 500   3,972.35 (-2.85%)
DOW   31,867.80 (-2.41%)
QQQ   296.14 (-3.28%)
AAPL   143.54 (-3.82%)
MSFT   257.25 (-3.59%)
FB   196.07 (-3.23%)
GOOGL   2,263.13 (-2.85%)
AMZN   2,183.86 (-5.35%)
TSLA   731.31 (-3.98%)
NVDA   173.93 (-4.31%)
BABA   89.37 (-2.85%)
NIO   16.25 (-2.29%)
AMD   98.77 (-3.61%)
CGC   5.77 (-2.04%)
MU   72.02 (-3.30%)
T   20.46 (-0.53%)
GE   75.65 (-0.98%)
F   13.02 (-3.77%)
DIS   105.81 (-2.60%)
AMC   13.47 (+4.42%)
PFE   50.58 (-1.48%)
PYPL   78.10 (-2.07%)
NFLX   182.77 (-4.09%)
S&P 500   3,972.35 (-2.85%)
DOW   31,867.80 (-2.41%)
QQQ   296.14 (-3.28%)
AAPL   143.54 (-3.82%)
MSFT   257.25 (-3.59%)
FB   196.07 (-3.23%)
GOOGL   2,263.13 (-2.85%)
AMZN   2,183.86 (-5.35%)
TSLA   731.31 (-3.98%)
NVDA   173.93 (-4.31%)
BABA   89.37 (-2.85%)
NIO   16.25 (-2.29%)
AMD   98.77 (-3.61%)
CGC   5.77 (-2.04%)
MU   72.02 (-3.30%)
T   20.46 (-0.53%)
GE   75.65 (-0.98%)
F   13.02 (-3.77%)
DIS   105.81 (-2.60%)
AMC   13.47 (+4.42%)
PFE   50.58 (-1.48%)
PYPL   78.10 (-2.07%)
NFLX   182.77 (-4.09%)
S&P 500   3,972.35 (-2.85%)
DOW   31,867.80 (-2.41%)
QQQ   296.14 (-3.28%)
AAPL   143.54 (-3.82%)
MSFT   257.25 (-3.59%)
FB   196.07 (-3.23%)
GOOGL   2,263.13 (-2.85%)
AMZN   2,183.86 (-5.35%)
TSLA   731.31 (-3.98%)
NVDA   173.93 (-4.31%)
BABA   89.37 (-2.85%)
NIO   16.25 (-2.29%)
AMD   98.77 (-3.61%)
CGC   5.77 (-2.04%)
MU   72.02 (-3.30%)
T   20.46 (-0.53%)
GE   75.65 (-0.98%)
F   13.02 (-3.77%)
DIS   105.81 (-2.60%)
AMC   13.47 (+4.42%)
PFE   50.58 (-1.48%)
PYPL   78.10 (-2.07%)
NFLX   182.77 (-4.09%)

Sensei Biotherapeutics (SNSE) Stock Forecast, Price & News

$1.69
-0.01 (-0.59%)
(As of 05/18/2022 11:43 AM ET)
Add
Compare
Today's Range
$1.69
$1.74
50-Day Range
$1.49
$3.03
52-Week Range
$1.45
$15.12
Volume
588 shs
Average Volume
94,724 shs
Market Capitalization
$51.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.79
30 days | 90 days | 365 days | Advanced Chart
Receive SNSE News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Sensei Biotherapeutics logo

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNSE
Fax
N/A
Employees
56
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.79 per share

Profitability

Net Income
$-36.79 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$51.76 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/18/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.12 out of 5 stars

Medical Sector

455th out of 1,426 stocks

Pharmaceutical Preparations Industry

196th out of 680 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Sensei Biotherapeutics (NASDAQ:SNSE) Frequently Asked Questions

Is Sensei Biotherapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sensei Biotherapeutics stock.
View analyst ratings for Sensei Biotherapeutics
or view top-rated stocks.

When is Sensei Biotherapeutics' next earnings date?

Sensei Biotherapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Sensei Biotherapeutics
.

How were Sensei Biotherapeutics' earnings last quarter?

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) issued its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.05.
View Sensei Biotherapeutics' earnings history
.

What price target have analysts set for SNSE?

5 brokers have issued twelve-month price objectives for Sensei Biotherapeutics' shares. Their forecasts range from $10.00 to $14.00. On average, they anticipate Sensei Biotherapeutics' share price to reach $12.50 in the next year. This suggests a possible upside of 639.6% from the stock's current price.
View analysts' price targets for Sensei Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sensei Biotherapeutics' key executives?
Sensei Biotherapeutics' management team includes the following people:
  • Mr. John K. Celebi M.B.A., MBA, Pres, CEO & Director (Age 50, Pay $532.63k)
  • Dr. Robert Hamilton Pierce M.D., Chief R&D Officer (Age 58, Pay $488.03k) (LinkedIn Profile)
  • Ms. Erin Colgan, Chief Financial Officer (Age 41)
  • Dr. Steven A. Fuller, Chief Biopharmaceuticals Devel. Officer
  • Ms. Lora Pike, VP of Investor Relations & Communications
  • Ms. Elisabeth Colunio, VP of HR
  • Mr. Edward van der Horst Ph.D., Sr. VP of TMAb Research
  • Dr. Michael Boychyn Ph.D., Sr. VP of Technical Operations & Maryland Site Head
  • Dr. Hanspeter Waldner Ph.D., Sr. VP of Cancer Immunology
When did Sensei Biotherapeutics IPO?

(SNSE) raised $100 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO.

What is Sensei Biotherapeutics' stock symbol?

Sensei Biotherapeutics trades on the NASDAQ under the ticker symbol "SNSE."

Who are Sensei Biotherapeutics' major shareholders?

Sensei Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.81%), State Street Corp (0.74%), Renaissance Technologies LLC (0.27%), HighTower Advisors LLC (0.16%), Leo Brokerage LLC (0.05%) and UBS Group AG (0.04%). Company insiders that own Sensei Biotherapeutics stock include Cambrian Biopharma Inc, James Peyer, Robert Hamilton Pierce and Thomas G Ricks.
View institutional ownership trends for Sensei Biotherapeutics
.

Which major investors are selling Sensei Biotherapeutics stock?

SNSE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and UBS Group AG.
View insider buying and selling activity for Sensei Biotherapeutics
or view top insider-selling stocks.

Which major investors are buying Sensei Biotherapeutics stock?

SNSE stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, HighTower Advisors LLC, State Street Corp, Leo Brokerage LLC, Raymond James & Associates, and Jane Street Group LLC. Company insiders that have bought Sensei Biotherapeutics stock in the last two years include Cambrian Biopharma Inc, James Peyer, and Thomas G Ricks.
View insider buying and selling activity for Sensei Biotherapeutics
or or view top insider-buying stocks.

How do I buy shares of Sensei Biotherapeutics?

Shares of SNSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sensei Biotherapeutics' stock price today?

One share of SNSE stock can currently be purchased for approximately $1.69.

How much money does Sensei Biotherapeutics make?

Sensei Biotherapeutics has a market capitalization of $51.76 million. The company earns $-36.79 million in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does Sensei Biotherapeutics have?

Sensei Biotherapeutics employs 56 workers across the globe.

What is Sensei Biotherapeutics' official website?

The official website for Sensei Biotherapeutics is www.senseibio.com.

How can I contact Sensei Biotherapeutics?

Sensei Biotherapeutics' mailing address is 1405 RESEARCH BLVD SUITE 125, ROCKVILLE MD, 20850. The company can be reached via phone at 240-243-8000 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.